Increased tissue factor pathway inhibitor and homocysteine in Alzheimer's disease

Neurobiology of Aging

Volumn 33, Issue 2, 2012, Pages 226-233

  Piazza, Fabrizio ^a   Galimberti, Gloria ^a   Conti, Elisa ^a   Isella, Valeria ^a   Perlangeli, Maria V ^a   Speranza, Tiziana ^b   Borroni, Barbara ^c   Pogliani, Enrico M ^b   Padovani, Alessandro ^c   Ferrarese, Carlo ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Alzheimer's disease; Endothelial injury; Homocysteine; Tissue factor pathway inhibitor

Indexed keywords

FOLIC ACID; HOMOCYSTEINE; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ALZHEIMER DISEASE; ARTICLE; BLOOD VESSEL INJURY; CAUSAL ATTRIBUTION; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; FEMALE; HOMOCYSTEINE; HUMANS; LIPOPROTEINS; MALE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 82755176503     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.02.016     Document Type: Article

References (44)

1. Adams M.J., Thom J., Hankey G.J., Baker R., Gilmore G., Staton J., Eikelboom J.W. The tissue factor pathway in ischemic stroke. Blood Coagul. Fibrinolysis 2006, 17:527-532.
2. Bell R.D., Zlokovic B.V. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 2009, 118:103-113.
3. Borroni B., Volpi R., Martini G., Del Bono R., Archetti S., Colciaghi F., Akkawi N.M., Di L.M., Romanelli G., Caimi L., Padovani A. Peripheral blood abnormalities in Alzheimer disease: evidence for early endothelial dysfunction. Alzheimer Dis. Assoc. Disord 2002, 16:150-155.
4. Bostom A.G., Rosenberg I.H., Silbershatz H., Jacques P.F., Selhub J., D'Agostino R.B., Wilson P.W., Wolf P.A. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann. Intern. Med 1999, 131:352-355.
5. Butenas S., Orfeo T., Mann K.G. Tissue factor in coagulation. Which? Where? When?. Arterioscler. Thromb. Vasc. Biol 2009, 29:1989-1996.
6. Das R.R., Seshadri S., Beiser A.S., Kelly-Hayes M., Au R., Himali J.J., Kase C.S., Benjamin E.J., Polak J.F., O'Donnell C.J., Yoshita M., D'Agostino R.B., Decarli C., Wolf P.A. Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study. Stroke 2008, 39:2929-2935.
7. De La Torre J.C. Cerebral hypoperfusion, capillary degeneration, and development of Alzheimer disease. Alzheimer Dis. Assoc. Disord 2000, 14(Suppl 1):S72-S81.
8. De La Torre J.C. Is Alzheimer's disease preceded by neurodegeneration or cerebral hypoperfusion?. Ann. Neurol 2005, 57:783-784.
9. Del Bo R., Comi G.P., Bresolin N., Castelli E., Conti E., Degiuli A., Ausenda C.D., Scarlato G. The apolipoprotein E epsilon4 allele causes a faster decline of cognitive performances in Down's syndrome subjects. J. Neurol. Sci 1997, 145:87-91.
10. den Heijer M., Koster T., Blom H.J., Bos G.M., Briet E., Reitsma P.H., Vandenbroucke J.P., Rosendaal F.R. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N. Engl. J. Med 1996, 334:759-762.
11. Flicker L., Martins R.N., Thomas J., Acres J., Taddei K., Vasikaran S.D., Norman P., Jamrozik K., Almeida O.P. B-vitamins reduce plasma levels of beta amyloid. Neurobiol. Aging 2008, 29:303-305.
12. Gelb D.J., Oliver E., Gilman S. Diagnostic criteria for Parkinson disease. Arch. Neurol 1999, 56:33-39.
13. Hamel E., Nicolakakis N., Aboulkassim T., Ongali B., Tong X.K. Oxidative stress and cerebrovascular dysfunction in mouse models of Alzheimer's disease. Exp. Physiol 2008, 93:116-120.
14. Hassan A., Hunt B.J., O'Sullivan M., Parmar K., Bamford J.M., Briley D., Brown M.M., Thomas D.J., Markus H.S. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain 2003, 126:424-432.
15. Hollister R.D., Kisiel W., Hyman B.T. Immunohistochemical localization of tissue factor pathway inhibitor-1 (TFPI-1), a Kunitz proteinase inhibitor, in Alzheimer's disease. Brain Res 1996, 728:13-19.
16. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev 2004, 5:347-360.
17. Jellinger K.A. The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol 2007, 113:349-388.
18. Kalaria R.N., Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis. Assoc. Disord 1999, 13(suppl 3):S115-S123.
19. Kamath A.F., Chauhan A.K., Kisucka J., Dole V.S., Loscalzo J., Handy D.E., Wagner D.D. Elevated levels of homocysteine compromise blood-brain barrier integrity in mice. Blood 2006, 107:591-593.
20. Leboeuf R. Homocysteine and Alzheimer's disease. J. Am. Diet. Assoc 2003, 103:304-307.
21. Lehmann M., Regland B., Blennow K., Gottfries C.G. Vitamin B12-B6-folate treatment improves blood-brain barrier function in patients with hyperhomocysteinaemia and mild cognitive impairment. Dement. Geriatr. Cognit. Disord 2003, 16:145-150.
22. Lwaleed B.A., Bass P.S. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J. Pathol 2006, 208:327-339.
23. McComb R.D., Miller K.A., Carson S.D. Tissue factor antigen in senile plaques of Alzheimer's disease. Am. J. Pathol 1991, 139:491-494.
24. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
25. Mackman N., Tilley R.E., Key N.S. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler. Thromb. Vasc. Biol 2007, 27:1687-1693.
26. Novo G., Caplice N., Tantillo R., Bonura F., Simari R., Novo S. TFPI antigen and activity levels in patients with asymptomatic atherosclerosis and target organ acute and chronic complications. Int. Angiol 2005, 24:366-371.
27. Novotny W.F., Girard T.J., Miletich J.P., Broze G.J. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J. Biol. Chem 1989, 264:18832-18837.
28. Ott I., Andrassy M., Zieglgansberger D., Geith S., Schomig A., Neumann F.J. Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1. Blood 2001, 97:3721-3726.
29. Perry I.J., Refsum H., Morris R.W., Ebrahim S.B., Ueland P.M., Shaper A.G. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995, 346:1395-1398.
30. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol 1999, 56:303-308.
31. Sandset P.M. Tissue factor pathway inhibitor (TFPI) - an update. Haemostasis 1996, 26(suppl 4):154-165.
32. Selhub J., Jacques P.F., Bostom A.G., D'Agostino R.B., Wilson P.W., Belanger A.J., O'Leary D.H., Wolf P.A., Schaefer E.J., Rosenberg I.H. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N. Engl. J. Med 1995, 332:286-291.
33. Seshadri S. Elevated plasma homocysteine levels: risk factor or risk marker for the development of dementia and Alzheimer's disease?. J. Alzheimers Dis 2006, 9:393-398.
34. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., Wilson P.W., Wolf P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med 2002, 346:476-483.
35. Seshadri S., Wolf P.A., Beiser A.S., Selhub J., Au R., Jacques P.F., Yoshita M., Rosenberg I.H., D'Agostino R.B., DeCarli C. Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch. Neurol 2008, 65:642-649.
36. Shi J., Perry G., Smith M.A., Friedland R.P. Vascular abnormalities: the insidious pathogenesis of Alzheimer's disease. Neurobiol. Aging 2000, 21:357-361.
37. Signorello M.G., Pascale R., Leoncini G. Effect of homocysteine on arachidonic acid release in human platelets. Eur. J. Clin. Invest 2002, 32:279-284.
38. Tangney C.C., Tang Y., Evans D.A., Morris M.C. Biochemical indicators of vitamin B(12) and folate insufficiency and cognitive decline. Neurology 2009, 72:361-367.
39. Thomas T., Thomas G., McLendon C., Sutton T., Mullan M. beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996, 380:168-171.
40. Tomimoto H., Akiguchi I., Suenaga T., Nishimura M., Wakita H., Nakamura S., Kimura J. Alterations of the blood-brain barrier and glial cells in white-matter lesions in cerebrovascular and Alzheimer's disease patients. Stroke 1996, 27:2069-2074.
41. van Oijen M., de Jong F.J., Witteman J.C., Hofman A., Koudstaal P.J., Breteler M.M. Atherosclerosis and risk for dementia. Ann. Neurol 2007, 61:403-410.
42. Welch G.N., Loscalzo J. Homocysteine and atherothrombosis. N. Engl. J. Med 1998, 338:1042-1050.
43. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005, 28:202-208.
44. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57:178-201.